MTX-101 is a product candidate based on a competitive inhibitor of the mitochondrial enzyme, succinate dehydrogenase (SDH), triggering a desired metabolic switch in the adult heart. Its novel mechanism of action is based on the groundbreaking discovery that reprogramming of the adult heart metabolism towards glycolysis instead of fatty acid oxidation promotes cardiomyocyte proliferation, angiogenesis, and resolution of fibrosis.
MTX-101, an injectable formulation of an SDH inhibitor, induces dynamic changes in adult cardiac metabolism. Proof-of-concept has been established in post-myocardial infarction (MI) models, demonstrating:
-
Cardiomyocyte proliferation in adult mice and pigs as well as in human cardiac organoids.
-
Restoration of the cardiac structure and function in mice with revascularization and no fibrosis.
By creating such therapies that restore heart function, Mount Therapeutics aims to revolutionize heart failure treatment and improve patient outcomes globally.
MTX-101
Mount Therapeutics, Inc. is developing MTX-101 as a unique injectable therapy to be administered for a couple of weeks to patients after acute MI to regenerate the heart muscle and provide normal heart function.
